TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04378036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hippotherapy Simulator
Description: Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
Study: NCT04129710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 250 mg/m2 over 3 hours on day3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated recombinant human granulocyte colony
Description: PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated recombinant human granulocyte colony
Description: PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGylated recombinant human granulocyte colony
Description: PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
Study: NCT02970526

Intervention type: DRUG
Intervention: Oxaliplatin
Description: Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
Study: NCT01271257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
Study: NCT02191540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abnoba Viscum F 20mg
Description: intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
Study: NCT01271257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
Study: NCT02882386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength Training
Study: NCT01908335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV high dose
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys /RBV
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study: NCT00613015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03167866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational SMS
Description: the participant receives a weekly text message that is aimed to increase motivation
Study: NCT00613015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03167866

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: informational SMS
Description: the participant a weekly text message that is provides information on improving lifestyle
Study: NCT02882386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Study: NCT04492306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dimethyl Sulfoxide
Description: DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3M ESPE Single bond 2
Description: Total etch adhesive bond

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3M ESPE Single bond 2
Description: Total etch adhesive bond

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)
Description: Composite Resin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)
Description: Composite Resin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3m ESPE etch
Description: 32% phosphoric acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3m ESPE etch
Description: 32% phosphoric acid
Study: NCT01058395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
Study: NCT02840903

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.
Study: NCT02882386

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk 1%

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate 80 (WPC-80)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microparticulated whey

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native whey
Study: NCT03976284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Garden-fresh produce and exercise
Description: The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
Study: NCT04474041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeQue Insight
Description: The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
Study: NCT03636607

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT dynamic scan
Description: The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT dynamic scan
Description: The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
Study: NCT00117689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: For a minimum of 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Between Day 3 the last dose of Thymoglobulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Between Day 3 the last dose of Thymoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: for at least 1 month posttransplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: for at least 1 month posttransplant
Study: NCT02282904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor peripheral blood stem cells.
Description: Infuse donor graft.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide post transplant
Description: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body 200cGy
Description: Day -1
Study: NCT02128321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: oral
Study: NCT01155973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDUCORE intervention
Description: Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: SCORE oral information and counseling as standard practice care
Study: NCT02394912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vena cava filter implantation (LUMIFI with Crux VCF System)
Study: NCT02282904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over one hour Day -6 and -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 over 30 minutes Day -6 through Day -2
Study: NCT03133572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supraglottic airway
Description: Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
Study: NCT02282904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
Study: NCT01504347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent recombinant OspA Lyme Borreliosis Vaccine
Description: Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent recombinant OspA Lyme Borreliosis Vaccine
Description: Booster vaccination 9-12 months after first vaccination in Section 1 subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent recombinant OspA Lyme Borreliosis Vaccine
Description: 3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
Study: NCT02488642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
Study: NCT02185989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early electrical stimulation and early leg bicycling added to early standard rehabilitation
Study: NCT03888118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luna EMG
Description: The duration of the overall therapeutic intervention in both groups will be the same.
Study: NCT03133572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face-mask
Description: In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
Study: NCT01535352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom-Net
Description: The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coach-facilitated Treatment as Usual
Description: Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
Study: NCT01143987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: starting with 25 mg daily dose with titration, maximum dose 100 mg daily
Study: NCT02458989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Use of a scalpel as a first incision during thyroid operation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery
Description: Use of an electrocautery as a first incision during thyroid operation
Study: NCT01707940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: BI144807 oral solution, intermediate dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: BI144807 oral solution, intermediate dose
Study: NCT00577421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 5 mg tablet of risedronate once a day for 2 years
Study: NCT00187733

Intervention type: OTHER
Intervention: Fasting blood and urine collection
Description: Not applicable no drugs dispensed
Study: NCT01930396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Tinzaparin)
Description: 0.9% Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Unfractionated Heparin)
Description: 0.9% Normal Saline
Study: NCT01873898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rex Medical Closer™ Vascular Closure System
Description: The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
Study: NCT02138838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
Study: NCT04853654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise training for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise training for 8 weeks
Study: NCT02205333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Monotherapy
Description: single intravenous (IV) administration of MEDI6469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Monotherapy
Description: single intravenous (IV) administration of MEDI6469
Study: NCT04853654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise training for 8 weeks
Study: NCT00780741

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Office Probing
Description: Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred Facility Probing
Description: Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
Study: NCT04327089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor
Study: NCT02205333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Plus Tremelimumab
Description: MEDI6469 in combination with Tremelimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Plus Tremelimumab
Description: MEDI6469 in combination with Tremelimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Plus Durvalumab
Description: MEDI6469 in combination with Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Plus Durvalumab
Description: MEDI6469 in combination with Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Plus Durvalumab
Description: MEDI6469 in combination with Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 plus Rituximab
Description: MEDI6469 in combination with Rituximab
Study: NCT01950091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitBack on-line intervention
Description: On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Website Control
Description: Intervention is a Menu of links to 4 popular Websites offering back pain education